ActiTrexx

ActiTrexx GmbH Aims to Prevent the Development of Graft-Versus-Host Disease at an Early Stage Through Cellular Therapy ATreg, Offering Hematopoietic Stem Cell Transplant Patients a Radical Treatment with Minimal Side Effects for the First Time. For transplant patients, ATreg represents a safe and effective therapeutic option that significantly improves survival rates and quality of life. ATreg addresses a significant unmet medical need and has the potential to overcome the inherent risks and limitations of current stem cell transplantation.